|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cadena DL and Gill GN: Receptor tyrosine
kinases. FASEB J. 6:2332–2337. 1992.PubMed/NCBI
|
|
6
|
Engelman JA and Cantley LC: The role of
the ErbB family members in non-small cell lung cancers sensitive to
epidermal growth factor receptor kinase inhibitors. Clin Cancer
Res. 12:S4372–S4376. 2006. View Article : Google Scholar
|
|
7
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sacher AG, Janne PA and Oxnard GR:
Management of acquired resistance to epidermal growth factor
receptor kinase inhibitors in patients with advanced non-small cell
lung cancer. Cancer. 120:2289–2298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bean J, Brennan C, Shih JY, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hobert O: Gene regulation by transcription
factors andmi-croRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV and Croce CM: MicroRNAs in
cancer: small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rolfo C, Fanale D, Hong DS, et al: Impact
of microRNAs in resistance to chemotherapy and novel targeted
agents in non-small cell lung cancer. Curr Pharm Biotechnol.
15:475–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedman JM and Jones PA: MicroRNAs:
critical mediators of differentiation, development and disease.
Swiss Med Wkly. 139:466–472. 2009.PubMed/NCBI
|
|
17
|
Moriya Y, Nohata N, Kinoshita T, et al:
Tumor suppressive microRNA-133a regulates novel molecular networks
in lung squamous cell carcinoma. J Hum Genet. 57:38–45. 2012.
View Article : Google Scholar
|
|
18
|
Goldstraw P, Crowley J, Chansky K, et al:
The IASLC Lung Cancer Staging Project: proposals for the revision
of the TNM stage groupings in the forthcoming (seventh) edition of
the TNM Classification of malignant tumours. J Thorac Oncol.
2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kojima S, Chiyomaru T, Kawakami K, et al:
Tumour suppressors miR-1 and miR-133a target the oncogenic function
of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J
Cancer. 106:405–413. 2012. View Article : Google Scholar :
|
|
20
|
Nohata N, Hanazawa T, Kinoshita T, et al:
Tumour-suppressive microRNA-874 contributes to cell proliferation
through targeting of histone deacetylase 1 in head and neck
squamous cell carcinoma. Br J Cancer. 108:1648–1658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kinoshita T, Nohata N, Hnasawa T, et al:
Tumour-suppressive microRNA-29s inhibit cancer cell migration and
invasion by targeting laminin-integrin signalling in head and neck
squamous cell carcinoma. Br J Cancer. 109:2636–2645. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshino H, Chiyomaru T, Enokida H, et al:
The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koeppen H, Yu W, Zha J, et al: Biomarker
analyses from a placebo-controlled phase II study evaluating
erlotinib ± onartuzumab in advanced non-small cell lung cancer: MET
expression levels are predictive of patient benefit. Clin Cancer
Res. 20:4488–4498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Itesako T, Seki N, Yoshino H, et al: The
microRNA expression signature of bladder cancer by deep sequencing:
the functional significance of the miR-195/497 cluster. PLoS One.
9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hidaka H, Seki N, Yoshino H, et al: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
26
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21.
2012.PubMed/NCBI
|
|
27
|
Georgantas R, Streicher K, Greenless L, et
al: MicroRNA-206 induces G1 arrest in melanoma by inhibition of
CDK4 and Cyclin D. Pigment Cell Melanoma Res. 27:275–286. 2014.
View Article : Google Scholar
|
|
28
|
Missiaglia E, Shepherd CJ, Patel S, et al:
MicroRNA-206 expression levels correlate with clinical behaviour of
rhabdomyosarcomas. Br J Cancer. 102:1769–1777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan D, da Dong XE, Chen X, et al:
MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma
development. J Biol Chem. 284:29596–29604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen X, Yan Q, Li S, et al: Expression of
the tumor suppressor miR-206 is associated with cellular
proliferative inhibition and impairs invasion in ERalpha-positive
endometrioid adenocarcinoma. Cancer Lett. 314:41–53. 2012.
View Article : Google Scholar
|
|
31
|
Kondo N, Toyama T, Sugiura H, et al:
miR-206 expression is down-regulated in estrogen receptor
alpha-positive human breast cancer. Cancer Res. 68:5004–5008. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shaw AT, Yeap BY, Solomon BJ, et al:
Effect of crizotinib on overall survival in patients with advanced
non-small-cell lung cancer harbouring ALK gene rearrangement: a
retrospective analysis. Lancet Oncol. 12:1004–1012. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scagliotti GV, Novello S and von Pawel J:
The emerging role of MET/HGF inhibitors in oncology. Cancer Treat
Rev. 39:793–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gately K, Forde L, Cuffe S, et al: High
coexpression of both EGFR and IGF1R correlates with poor patient
prognosis in resected non-small-cell lung cancer. Clin Lung Cancer.
15:58–66. 2014. View Article : Google Scholar
|
|
37
|
Maroun CR and Rowlands T: The Met receptor
tyrosine kinase: a key player in oncogenesis and drug resistance.
Pharmacol Ther. 142:316–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sadiq AA and Salgia R: MET as a possible
target for non-small-cell lung cancer. J Clin Oncol. 31:1089–1096.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cipriani NA, Abidoye OO, Vokes E and
Salgia R: MET as a target for treatment of chest tumors. Lung
Cancer. 63:169–179. 2009. View Article : Google Scholar :
|
|
40
|
Nasser MW, Datta J, Nuovo G, et al:
Down-regulation of micro-RNA-1 (miR-1)in lung cancer. Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Taulli R, Bersani F, Foglizzo V, et al:
The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma
growth in xenotransplanted mice by promoting myogenic
differentiation. J Clin Invest. 119:2366–2378. 2009.PubMed/NCBI
|
|
42
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Vandenboom TG II, Wang Z, et al:
miR-146a suppresses invasion of pancreatic cancer cells. Cancer
Res. 70:1486–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Acunzo M, Romano G, Palmieri D, et al:
Cross-talk between MET and EGFR in non-small cell lung cancer
involves miR-27a and Sprouty2. Proc Natl Acad Sci USA.
110:8573–8578. 2013. View Article : Google Scholar : PubMed/NCBI
|
